CCM
Catalio Capital Management Portfolio holdings
AUM
$541M
1-Year Est. Return
81.05%
1 Year Est. Return
+81.05%
AUM
$541M
AUM Growth
+$64M
(+13%)
Holding
50
Top Buys
| 1 | +$35.9M | |
| 2 | +$19.9M | |
| 3 | +$13.8M | |
| 4 |
Supernus Pharmaceuticals
SUPN
|
+$13.7M |
| 5 |
Exact Sciences
EXAS
|
+$13.6M |
Top Sells
| 1 | +$30.6M | |
| 2 | +$25.2M | |
| 3 | +$19.6M | |
| 4 |
Corcept Therapeutics
CORT
|
+$17.6M |
| 5 |
BridgeBio Pharma
BBIO
|
+$15.8M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Eli Lilly
LLY
$908B
| $43.8M | 8.09% |
57,376
+3,460
|
|
||
2
AbbVie
ABBV
$404B
| $35.9M | 6.63% |
+154,834
|
|
||
|
3
BridgeBio Pharma
BBIO
$14.4B
| $32.3M | 5.98% |
622,729
-304,982
|
|
||
4
Intuitive Surgical
ISRG
$202B
| $31.9M | 5.9% |
71,343
+14,669
|
|
||
5
Ascendis Pharma
ASND
$12.7B
| $28.8M | 5.33% |
144,954
-34,972
|
|
||
6
Soleno Therapeutics
SLNO
$2.83B
| $28.3M | 5.23% |
418,245
+8,301
|
|
||
7
Dianthus Therapeutics
DNTH
$1.93B
| $26.3M | 4.86% |
667,615
-78,912
|
|
||
8
Boston Scientific
BSX
$145B
| $25.7M | 4.75% |
262,972
+33,926
|
|
||
9
Syndax Pharmaceuticals
SNDX
$1.72B
| $24.8M | 4.59% |
1,614,717
-489,795
|
|
||
10
Cytokinetics
CYTK
$8.16B
| $24.8M | 4.59% |
451,581
-149,858
|
|
||
11
Natera
NTRA
$33.5B
| $23.9M | 4.42% |
148,369
+51,072
|
|
||
12
Regeneron Pharmaceuticals
REGN
$76B
| $19.9M | 3.67% |
+35,344
|
|
||
13
Structure Therapeutics
GPCR
$1.99B
| $18.3M | 3.37% |
651,810
-18,765
|
|
||
14
uniQure
QURE
$1.44B
| $16.5M | 3.05% |
282,940
-134,503
|
|
||
15
Disc Medicine
IRON
$3.54B
| $14.3M | 2.65% |
216,527
+185,866
|
|
||
|
ABVX
16
Abivax
ABVX
$8.54B
| $13.8M | 2.54% |
+162,141
|
|
||
|
17
Supernus Pharmaceuticals
SUPN
$2.57B
| $13.7M | 2.54% |
+287,090
|
|
||
|
18
Exact Sciences
EXAS
$19.2B
| $13.6M | 2.52% |
+248,987
|
|
||
19
Phathom Pharmaceuticals
PHAT
$1.04B
| $13.3M | 2.46% |
1,128,521
+456,231
|
|
||
20
Adaptive Biotechnologies
ADPT
$2.64B
| $13.2M | 2.45% |
884,890
-511,555
|
|
||
21
Avidity Biosciences
RNA
$10.8B
| $11.5M | 2.12% |
+263,256
|
|
||
22
ADMA Biologics
ADMA
$4.8B
| $10M | 1.86% |
684,508
+114,804
|
|
||
23
Ultragenyx Pharmaceutical
RARE
$3.53B
| $8.76M | 1.62% |
291,262
+77,860
|
|
||
24
Fractyl Health
GUTS
$273M
| $8.29M | 1.53% |
5,214,236
+5,000,000
|
|
||
|
GRAL
25
GRAIL Inc
GRAL
$4.1B
| $8.16M | 1.51% |
+137,928
|
|